TOKYO & BOSTON--(BUSINESS WIRE)--Bain Capital, a leading global private investment firm, today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation ...

Bain Capital, a global private investment firm, has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma ...

Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...

U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth 510 billion yen ($3.4 billion), ...

MTPC employs over 5,000 people globally. As an independent company, Tanabe Pharma will continue to build on its legacy of medical innovation while developing new opportunities for growth through ...

Following rumblings of a private equity bidding war late last year, Bain Capital has emer | Bain Capital is laying out 510 ...

today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation (“Tanabe Pharma”, “MTPC” or “the Company”) in a carve-out transaction from ...

TOKYO, Feb 7 (Reuters) - U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth ... from Japanese authorities to raise corporate and shareholder value.

Bain Capital said the deal came about following several recent initiatives by the Japanese government and regulators to ...

Bain Capital, an investment firm that has spread its life sciences bets mainly across companies developing novel new medicines, is acquiring Mitsubishi Tanabe Pharma Corporation in a multi-billion ...

Bain Capital has agreed to acquire Tanabe Pharma, the pharma arm of Mitsubishi Chemical Group Corporation. The deal puts Tanabe Pharma at a valuation of about $3.3 billion. Founded in 1678, Tanabe ...

TOKYO :U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth 510 ... from Japanese authorities to raise corporate and shareholder value. Bain and other foreign ...